Michael Henrickson, MD, MPH

Clinical Director, Division of Rheumatology

Associate Professor, UC Department of Pediatrics

Phone 513-636-7686

Email michael.henrickson@cchmc.org

Health policy, global health, neuropsychiatric-SLE, periodic fever syndromes, systemic JIA, culturally appropriate care, quality measures.

BA: Emory University, Atlanta, GA, 1980.

MD: Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, 1984.

MPH: College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2009.

Residency: Tripler Army Medical Center, Honolulu, HI, 1984-87.

Fellowship: Children’s Hospital Medical Center, Cincinnati, OH, 1991-94.

Certification: American Board of Pediatrics: General Pediatrics, 1988 (recertified 2004). Pediatric Rheumatology, 1994 (recertified 2008). National Board of Public Health Examiners, 2009.   

Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6.

Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804.

Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, Solís-Vallejo E, Huang B, Grom AA, Lovell DJ. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):907-14.

Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Transplantation. 1995 Oct 27;60(8):828-35.

Henrickson M, Giannini EH, Hirsch R. Reduction of mortality and lymphadenopathy in MRL-lpr/lpr mice treated with nonmitogenic anti-CD3 monoclonal antibody. Arthritis Rheum. 1994 Apr;37(4):587-94.